Douglas W. Blayney, MD, FASCO, Clinical researcher and breast oncologist, Professor of Medicine at Stanford University. In this video, he speaks about the ASCO 2022 Abstract – Real-world effectiveness of prophylactic granulocyte colony-stimulating factor (G-CSF) early (week 1) and late (weeks 2-3) in the cycle for the prevention of febrile neutropenia (FN) among patients (pts) with breast cancer (BC) after high FN"“risk chemotherapy (chemo).
Overview:
The major goal of this study is to compare the percentage of patients with DSN =0 in patients treated with:
Docetaxel, doxorubicin, and cyclophosphamide (TAC) plus pegfilgrastim versus TAC + plinabulin/pegfilgrastim combo
Severe neutropenia is defined as an absolute neutrophil count (ANC) of 0.5109/L.
The chemotherapy in this study will consist of docetaxel, doxorubicin, and cyclophosphamide (TAC).